Format

Send to

Choose Destination
Semin Oncol. 2013 Oct;40(5):549-53. doi: 10.1053/j.seminoncol.2013.07.009.

Clinical translation in multiple myeloma: from bench to bedside.

Author information

1
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA. Electronic address: jacob_laubach@dfci.harvard.edu.

Abstract

The outlook for patients with multiple myeloma (MM) has improved significantly with the development of new and more effective therapies, particularly the immunomodulatory agents and proteasome inhibitors. Preclinical and correlative science investigations have played a critical role in these advances, providing important insights regarding mechanisms of neoplasia, inhibition of tumor growth, and drug resistance. This review highlights the evolution of drug development in MM, the manner in which preclinical models have contributed to the process of drug discovery, and important insights gained during the current era of MM drug development.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center